Procanbid is a drug owned by King Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 12, 2014. Details of Procanbid's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5656296 | Dual control sustained release drug delivery systems and methods for preparing same |
Aug, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Procanbid is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Procanbid's family patents as well as insights into ongoing legal events on those patents.
Procanbid's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Procanbid's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 12, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Procanbid Generic API suppliers:
Procainamide Hydrochloride is the generic name for the brand Procanbid. 25 different companies have already filed for the generic of Procanbid, with Watson Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Procanbid's generic
About Procanbid
Procanbid is a drug owned by King Pharmaceuticals Inc. Procanbid uses Procainamide Hydrochloride as an active ingredient. Procanbid was launched by King Pharms in 1996.
Approval Date:
Procanbid was approved by FDA for market use on 31 January, 1996.
Active Ingredient:
Procanbid uses Procainamide Hydrochloride as the active ingredient. Check out other Drugs and Companies using Procainamide Hydrochloride ingredient
Dosage:
Procanbid is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 1GM | TABLET, EXTENDED RELEASE | Discontinued | ORAL |